CN1561387A - 益生菌双歧杆菌菌株 - Google Patents

益生菌双歧杆菌菌株 Download PDF

Info

Publication number
CN1561387A
CN1561387A CNA028185773A CN02818577A CN1561387A CN 1561387 A CN1561387 A CN 1561387A CN A028185773 A CNA028185773 A CN A028185773A CN 02818577 A CN02818577 A CN 02818577A CN 1561387 A CN1561387 A CN 1561387A
Authority
CN
China
Prior art keywords
prescription
bifidobacterium strains
inflammatory
disease
strains
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA028185773A
Other languages
English (en)
Chinese (zh)
Inventor
约翰·凯文·柯林斯
杰拉尔德·克里斯托弗·奥沙利文
利亚姆·奥马霍尼
弗格斯·沙纳汉
巴里·基利
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
PrecisionBiotics Group Ltd
Original Assignee
Alimentary Health Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alimentary Health Ltd filed Critical Alimentary Health Ltd
Publication of CN1561387A publication Critical patent/CN1561387A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/745—Bifidobacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C12N1/205—Bacterial isolates
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2400/00—Lactic or propionic acid bacteria
    • A23V2400/51—Bifidobacterium
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2400/00—Lactic or propionic acid bacteria
    • A23V2400/51—Bifidobacterium
    • A23V2400/533—Longum
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/02—Acetobacter

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Mycology (AREA)
  • Diabetes (AREA)
  • Virology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Nutrition Science (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Polymers & Plastics (AREA)
  • Obesity (AREA)
CNA028185773A 2001-07-26 2002-07-26 益生菌双歧杆菌菌株 Pending CN1561387A (zh)

Applications Claiming Priority (12)

Application Number Priority Date Filing Date Title
IE010717 2001-07-26
IE20010710 2001-07-26
IE20010717 2001-07-26
IE20010714 2001-07-26
IE010714 2001-07-26
IE010709 2001-07-26
IE010711 2001-07-26
IE20010713 2001-07-26
IE20010711 2001-07-26
IE010710 2001-07-26
IE20010709 2001-07-26
IE010713 2001-07-26

Publications (1)

Publication Number Publication Date
CN1561387A true CN1561387A (zh) 2005-01-05

Family

ID=27547373

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA028185773A Pending CN1561387A (zh) 2001-07-26 2002-07-26 益生菌双歧杆菌菌株

Country Status (12)

Country Link
US (2) US20030092163A1 (enExample)
EP (1) EP1409644A1 (enExample)
JP (1) JP2005508617A (enExample)
CN (1) CN1561387A (enExample)
AU (1) AU2002329006A1 (enExample)
BR (1) BR0211442A (enExample)
CA (1) CA2454803A1 (enExample)
IL (1) IL160048A0 (enExample)
IN (1) IN2004KN00093A (enExample)
MX (1) MXPA04000738A (enExample)
PE (1) PE20030284A1 (enExample)
WO (1) WO2003010297A1 (enExample)

Cited By (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100480370C (zh) * 2002-07-23 2009-04-22 雀巢技术公司 用于消化道神经肌肉功能的益生菌
CN101909643A (zh) * 2007-11-30 2010-12-08 巴斯德研究所 干酪乳杆菌菌株用于制备抑制肥大细胞活化之组合物的用途
CN102899261A (zh) * 2011-03-11 2013-01-30 光晟生物科技股份有限公司 可产生高免疫激活反应的长双歧杆菌长亚种分离株及可刺激免疫激活的组合物
CN101983237B (zh) * 2007-12-24 2013-06-12 康斯乔最高科学研究公司 改善与谷蛋白摄入相关之病症个体健康状况的微生物
CN103561752A (zh) * 2011-03-09 2014-02-05 明尼苏达大学评议会 用于移植结肠微生物群的组合物和方法
CN103623010A (zh) * 2007-05-18 2014-03-12 雀巢产品技术援助有限公司 在外科手术前和/或外科手术后环境中的益生菌
CN104784694A (zh) * 2009-06-19 2015-07-22 杜邦营养生物科学有限公司 治疗糖尿病及相关病症的双歧杆菌
US9320763B2 (en) 2000-07-25 2016-04-26 Thomas Julius Borody Probiotic recolonisation therapy
US9901603B2 (en) 2015-05-14 2018-02-27 Crestovo Holdings Llc Compositions for fecal floral transplantation and methods for making and using them and device for delivering them
US9962413B2 (en) 2010-08-04 2018-05-08 Crestovo Holdings Llc Compositions for fecal floral transplantation and methods for making and using them and devices for delivering them
US10092601B2 (en) 2016-10-11 2018-10-09 Crestovo Holdings Llc Compositions and methods for treating multiple sclerosis and related disorders
US10195235B2 (en) 2016-08-03 2019-02-05 Crestovo Holdings Llc Methods for treating ulcerative colitis
CN109929773A (zh) * 2019-01-10 2019-06-25 江苏德禧生物科技有限公司 一株可用于富硒培养的双歧杆菌及其活性蛋白和应用
US11026978B2 (en) 2016-10-11 2021-06-08 Finch Therapeutics Holdings Llc Compositions and methods for treating multiple sclerosis and related disorders
US11040073B2 (en) 2017-04-05 2021-06-22 Finch Therapeutics Holdings Llc Compositions and methods for treating diverticulitis and related disorders
US11166990B2 (en) 2018-07-13 2021-11-09 Finch Therapeutics Holdings Llc Methods and compositions for treating ulcerative colitis
US11202808B2 (en) 2015-05-22 2021-12-21 Arizona Board Of Regents On Behalf Of Arizona State University Methods for treating autism spectrum disorder and associated symptoms
CN113862175A (zh) * 2014-12-23 2021-12-31 4D制药研究有限公司 免疫调控
US11213549B2 (en) 2016-10-11 2022-01-04 Finch Therapeutics Holdings Llc Compositions and method for treating primary sclerosing cholangitis and related disorders
US11357801B2 (en) 2016-06-15 2022-06-14 Arizona Board Of Regents On Behalf Of Arizona State University Methods for treating autism spectrum disorder and associated symptoms
US11433102B2 (en) 2017-04-05 2022-09-06 Finch Therapeutics Holdings Llc Compositions and methods for treating Parkinson's disease (PD) and related disorders
US11542560B2 (en) 2012-05-25 2023-01-03 Board of Regents on Behalf of Arizona State University Microbiome markers and therapies for autism spectrum disorders
CN116083327A (zh) * 2023-04-07 2023-05-09 天赋能(天津)功能食品研究发展有限公司 长双歧杆菌婴儿亚种及在缓解便秘、抗结肠组织炎症和改善肠道菌群方面的应用
CN116574659A (zh) * 2023-06-14 2023-08-11 江南大学 一株可缓解类风湿性关节炎的长双歧杆菌婴儿亚种及其应用
US11819523B2 (en) 2016-07-01 2023-11-21 Regents Of The University Of Minnesota Compositions and methods for C. difficile treatment
US11865145B2 (en) 2017-08-07 2024-01-09 Finch Therapeutics Holdings Llc Compositions and methods for maintaining and restoring a healthy gut barrier
US11890306B2 (en) 2017-05-26 2024-02-06 Finch Therapeutics Holdings Llc Lyophilized compositions comprising fecal microbe-based therapeutic agents and methods for making and using same
US11911419B2 (en) 2018-09-27 2024-02-27 Finch Therapeutics Holdings Llc Compositions and methods for treating epilepsy and related disorders
US12290538B2 (en) 2019-07-19 2025-05-06 Finch Therapeutics Holdings Llc Methods and products for treatment of gastrointestinal disorders

Families Citing this family (93)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8563522B2 (en) 1997-07-08 2013-10-22 The Iams Company Method of maintaining and/or attenuating a decline in quality of life
US7182943B2 (en) * 2002-05-15 2007-02-27 UNIVERSITé LAVAL Method and system for modulation of microbial cell characteristics
SE526711C2 (sv) * 2003-01-31 2005-10-25 Probi Ab Nya stammar av Bifidobacterium med förmåga att överleva i magtarmkanalen och producera glutamin in vivo, samt kompositioner och användningar därav
US20040197304A1 (en) 2003-04-01 2004-10-07 The Procter & Gamble Company And Alimentary Health, Ltd. Methods of determining efficacy of treatments of inflammatory diseases of the bowel
EP2280286A1 (en) * 2003-09-15 2011-02-02 Oklahoma Medical Research Foundation Method of using cytokine assays to diagnose, treat, and evaluate systemic lupus erythematosus
WO2005030230A1 (en) * 2003-09-30 2005-04-07 Probiomics Limited Compositions and methods for treatment or prevention of psoriasis and related disorders
GB0323039D0 (en) * 2003-10-01 2003-11-05 Danisco Method
AU2004275438B2 (en) * 2003-10-01 2008-05-29 Commonwealth Scientific & Industrial Research Organisation Probiotic storage and delivery
US8871266B2 (en) 2003-10-01 2014-10-28 Commonwealth Scientific & Industrial Research Organisation Probiotic storage and delivery
US20090257993A1 (en) 2003-12-17 2009-10-15 M Rabet Laura Lactic Acid Producing Bacteria and Lung Function
US20050158294A1 (en) 2003-12-19 2005-07-21 The Procter & Gamble Company Canine probiotic Bifidobacteria pseudolongum
US7785635B1 (en) 2003-12-19 2010-08-31 The Procter & Gamble Company Methods of use of probiotic lactobacilli for companion animals
US8877178B2 (en) 2003-12-19 2014-11-04 The Iams Company Methods of use of probiotic bifidobacteria for companion animals
US8894991B2 (en) 2003-12-19 2014-11-25 The Iams Company Canine probiotic Lactobacilli
US20050152884A1 (en) 2003-12-19 2005-07-14 The Procter & Gamble Company Canine probiotic Bifidobacteria globosum
WO2005072718A1 (ja) * 2004-01-28 2005-08-11 Kurume University 乳清発酵物を含有する医薬組成物
JP2005247780A (ja) * 2004-03-05 2005-09-15 Masakazu Maruyama ウイルス性肝炎治療剤
ES2262418B1 (es) * 2004-12-28 2007-11-01 Consejo Superior Investig. Cientificas Extractos proteicos con amplio espectro de actividad antibacteriana y cepas del genero bifidobacterium que los producen.
TW200700074A (en) * 2005-03-04 2007-01-01 Calpis Co Ltd Inducer of t cell apoptosis
WO2006097949A1 (en) * 2005-03-16 2006-09-21 Actial Farmacêutica, Lda. Mixture of at least 6 species of lactic acid bacteria and/or bifidobacteria in the manufacture of sourdough
EP2308566B1 (en) 2005-04-08 2017-07-05 The Procter and Gamble Company Use of orally administered probiotic bifidobacteria for human beauty benefits
AU2011205121B2 (en) * 2005-04-08 2012-07-05 Alimentary Health Ltd Method of use of orally administered probiotic bifidobacteria for human beauty benefits
DE602006006997D1 (de) * 2005-05-16 2009-07-09 Univ Liege Probiotische bifidobacterium arten
JP4938006B2 (ja) 2005-05-31 2012-05-23 ザ・アイムス・カンパニー ネコ科動物プロバイオティク・ビフィドバクテリア
EP2261323A1 (en) 2005-05-31 2010-12-15 The Iams Company Feline probiotic lactobacilli
US20090257995A1 (en) 2005-11-18 2009-10-15 Idemitsu Kosan Co., Ltd. Harmful bacterium control agent containing bacillus thuringiensis
GB0524103D0 (en) * 2005-11-26 2006-01-04 Medical Res Council Healing
US7943328B1 (en) 2006-03-03 2011-05-17 Prometheus Laboratories Inc. Method and system for assisting in diagnosing irritable bowel syndrome
US20090170772A1 (en) * 2006-03-31 2009-07-02 Morinaga Milk Industry Co., Ltd. Interleukin production regulator, pharmaceutical composition or food comprising the interleukin production regulator, and method for production of the interleukin production regulator
US20080085524A1 (en) * 2006-08-15 2008-04-10 Prometheus Laboratories Inc. Methods for diagnosing irritable bowel syndrome
US20100094560A1 (en) * 2006-08-15 2010-04-15 Prometheus Laboratories Inc. Methods for diagnosing irritable bowel syndrome
US20080118473A1 (en) * 2006-11-01 2008-05-22 The Procter & Gamble Company Methods of treating a respiratory condition comprising probiotic treatment
ATE521358T1 (de) * 2007-01-17 2011-09-15 Meiji Co Ltd Vorbeugender und/oder therapeutischer wirkstoff zur behandlung einer funktionellen gastrointestinalen erkrankung
WO2008093303A2 (en) 2007-02-01 2008-08-07 The Iams Company Method for decreasing inflammation and stress in a mammal using glucose antimetaboltes, avocado or avocado extracts
US9408818B2 (en) * 2007-02-28 2016-08-09 Mead Johnson Nutrition Company Method for the utilization of and product containing inactivated probiotic
NZ580006A (en) 2007-03-28 2012-03-30 Alimentary Health Ltd Probiotic bifidobacterium strain 41387
US8557233B2 (en) * 2007-03-28 2013-10-15 Alimentary Heath Limited Probiotic bifidobacterium strains
ES2523575T3 (es) 2007-06-27 2014-11-27 Laboratorios Ordesa, S.L. Una nueva cepa de bifidobacterium y peptidos acitvos contra infecciones por rotavirus
US9771199B2 (en) 2008-07-07 2017-09-26 Mars, Incorporated Probiotic supplement, process for making, and packaging
US20110189149A1 (en) * 2008-06-20 2011-08-04 Remy Burcelin New Uses of Lactic Acid Bacteria and Bifidobacteria
US10104903B2 (en) 2009-07-31 2018-10-23 Mars, Incorporated Animal food and its appearance
EP2289527B1 (en) * 2009-08-25 2018-02-21 Nestec S.A. Bifidobacterium longum and functional GI disorders
EP2485744A4 (en) * 2009-10-09 2014-01-22 Prothera Inc COMPOSITIONS AND METHODS COMPRISING THE PEDIOCOCCUS TO REDUCE AT LEAST ONE SYMPTOM ASSOCIATED WITH DEVELOPMENT-INVASIVE DISORDER IN A PERSON IN WHICH A DEVELOPMENT-INVASIVE DISORDER HAS BEEN DIAGNOSED
PL2498789T3 (pl) 2009-11-11 2017-01-31 Alimentary Health Limited Probiotyczny szczep bifidobacterium
WO2011148220A1 (en) 2010-05-28 2011-12-01 Compagnie Gervais Danone Probiotic strains for use in improving transepithelial resistance
WO2011148219A1 (en) 2010-05-28 2011-12-01 Compagnie Gervais Danone Probiotic strains for use in improving the enteric nervous system
US9011909B2 (en) 2010-09-03 2015-04-21 Wisconsin Pharmacal Company, Llc Prebiotic suppositories
ES2389547B1 (es) * 2010-12-07 2013-08-08 Consejo Superior De Investigaciones Científicas (Csic) Bifidobacterium cect 7765 y su uso en la prevención y/o tratamiento del sobrepeso, la obesidad y patologías asociadas.
EP2651423B1 (en) 2010-12-17 2015-09-30 Compagnie Gervais Danone Lactococcus lactis strains for use in improving digestive condition
GB201112091D0 (en) 2011-07-14 2011-08-31 Gt Biolog Ltd Bacterial strains isolated from pigs
GB201117313D0 (en) 2011-10-07 2011-11-16 Gt Biolog Ltd Bacterium for use in medicine
CN110055320A (zh) * 2012-03-17 2019-07-26 加州大学评议会 痤疮的快速诊断和个体化治疗
GB201306536D0 (en) 2013-04-10 2013-05-22 Gt Biolog Ltd Polypeptide and immune modulation
ITMI20131467A1 (it) * 2013-09-06 2015-03-07 Sofar Spa Uso di una composizione comprendente microrganismi per aumentare la produzione intestinale di acido butirrico, di acido folico o di niacina e/o per diminuire la produzione intestinale di acido succinico
US20150209468A1 (en) 2014-01-24 2015-07-30 The Procter & Gamble Company Hygiene article containing microorganism
CA2936110A1 (en) 2014-01-24 2015-07-30 The Procter & Gamble Company Web comprising a microorganism-containing fibrous element and method for making same
US20150209392A1 (en) 2014-01-24 2015-07-30 The Procter & Gamble Company Filaments Comprising a Microorganism and Method for Making Same
MA39710A (fr) 2014-04-23 2015-10-29 Sofar Spa Composition topique destinée à être utilisée dans le traitement d'une maladie inflammatoire de l'intestin
DK3193901T3 (en) 2014-12-23 2018-05-28 4D Pharma Res Ltd PIRIN POLYPEPTIDE AND IMMUNMODULATION
US20160354507A1 (en) 2015-06-07 2016-12-08 The Procter & Gamble Company Article of commerce containing absorbent article
EP3662917A1 (en) 2015-06-15 2020-06-10 4D Pharma Research Limited Compositions comprising bacterial strains
MA41010B1 (fr) 2015-06-15 2020-01-31 4D Pharma Res Ltd Compositions comprenant des souches bactériennes
MA41060B1 (fr) 2015-06-15 2019-11-29 4D Pharma Res Ltd Compositions comprenant des souches bactériennes
PE20180243A1 (es) 2015-06-15 2018-01-31 4D Pharma Res Ltd Composiciones que comprenden cepas bacterianas
LT3360559T (lt) 2015-06-15 2019-12-27 4D Pharma Research Limited Kompozicijos, apimančios bakterijų kamienus
US20170020750A1 (en) 2015-07-23 2017-01-26 The Procter & Gamble Company Patch containing microorganism
MA41013A (fr) 2015-11-20 2017-08-30 4D Pharma Res Ltd Compositions comprenant des souches bactériennes
GB201520497D0 (en) 2015-11-20 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
GB201520638D0 (en) 2015-11-23 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
GB201520631D0 (en) 2015-11-23 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
GB201612191D0 (en) 2016-07-13 2016-08-24 4D Pharma Plc Compositions comprising bacterial strains
MX373290B (es) 2016-03-04 2020-06-18 4D Pharma Plc Composiciones que comprenden cepas bacterianas.
EP3448398A4 (en) 2016-04-21 2019-12-18 Naked Biome, Inc. COMPOSITIONS AND METHODS FOR TREATING SKIN DISEASES
IT201600083376A1 (it) 2016-08-08 2018-02-08 Sofar Spa Uso di probiotici per aumentare l’assorbimento proteico
ITUA20164188A1 (it) 2016-06-08 2017-12-08 Sofar Spa Nuovo uso medico di probiotici
TWI802545B (zh) 2016-07-13 2023-05-21 英商４Ｄ製藥有限公司 包含細菌菌株之組合物
IT201600122724A1 (it) 2016-12-02 2018-06-02 Sofar Spa Exopolysaccharides and uses thereof
GB201621123D0 (en) 2016-12-12 2017-01-25 4D Pharma Plc Compositions comprising bacterial strains
IT201600127498A1 (it) 2016-12-16 2018-06-16 Sofar Spa Probiotici per uso nella diverticolosi e malattia diverticolare
EP3589726A1 (en) 2017-02-28 2020-01-08 Alimentary Health Limited Bifidobacterium longum able to beneficially modulate immune response to respiratory virus infection
ES2834950T3 (es) * 2017-02-28 2021-06-21 Prec Group Limited Bifidobacterium longum capaz de modular beneficiosamente la respuesta inmunitaria a la infección por virus respiratorio
MA48940A (fr) 2017-05-22 2020-04-08 4D Pharma Res Ltd Compositions comprenant des souches bactériennes
MA41708A (fr) 2017-05-24 2020-04-08 4D Pharma Res Ltd Compositions comprenant des souches bactériennes
TWI767013B (zh) 2017-06-14 2022-06-11 英商4D製藥研究有限公司 包含細菌品系之組成物
JP2020523326A (ja) 2017-06-14 2020-08-06 フォーディー ファーマ リサーチ リミテッド４Ｄ Ｐｈａｒｍａ Ｒｅｓｅａｒｃｈ Ｌｉｍｉｔｅｄ 細菌株を含む組成物
PL3638271T3 (pl) 2017-06-14 2021-03-22 4D Pharma Research Limited Kompozycje zawierające szczepy bakteryjne
KR102563191B1 (ko) 2017-07-05 2023-08-02 에벨로 바이오사이언시즈, 인크. 비피도박테리움 애니멀리스 ssp. 락티스를 이용한 암 치료 조성물 및 방법
US20190298783A1 (en) * 2018-03-28 2019-10-03 Morinaga Milk Industry Co., Ltd. Composition for relieving stress, pharmaceutical composition and food and drink composition and method for relieving stress using the composition for relieving stress
CN108570434A (zh) * 2018-05-10 2018-09-25 苏州博悦曼环保科技有限公司 高效降解餐厨垃圾的复合菌剂及其制造方法
CN111411093B (zh) * 2019-04-30 2021-10-22 中国科学院天津工业生物技术研究所 活性提高的磷酸转酮酶及在生产代谢物中的应用
US11751597B2 (en) 2019-11-05 2023-09-12 Alfasigma S.P.A. Compositions comprising bacterial strains for use in increasing the bioavailability of amino acids derived from proteins, and related food product methods and systems
EP4117697A1 (en) 2020-03-13 2023-01-18 PrecisionBiotics Group Limited Bifidobacterium longum
CN119162041A (zh) * 2024-09-30 2024-12-20 内蒙古农业大学 青春双歧杆菌b-201及其活性物质的后生元制备和应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5902578A (en) * 1996-03-25 1999-05-11 Abbott Laboratories Method and formula for the prevention of diarrhea
US5902743A (en) * 1998-03-20 1999-05-11 Wisconsin Alumni Research Foundation Probiotic bifidobacterium strain
ID29150A (id) * 1999-01-15 2001-08-02 Entpr Ireland Cs Penggunaan lactobacillus salivarius

Cited By (84)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9623056B2 (en) 2000-07-20 2017-04-18 Crestovo Llc Probiotic recolonisation therapy
US9468658B2 (en) 2000-07-25 2016-10-18 Crestovo Llc Probiotic recolonisation therapy
US9610308B2 (en) 2000-07-25 2017-04-04 Crestovo Llc Probiotic recolonisation therapy
US9789140B2 (en) 2000-07-25 2017-10-17 Crestovo Holdings Llc Probiotic recolonisation therapy
US9867858B2 (en) 2000-07-25 2018-01-16 Crestovo Holdings Llc Probiotic recolonisation therapy
US9737574B2 (en) 2000-07-25 2017-08-22 Crestovo Llc Probiotic recolonisation therapy
US9682108B2 (en) 2000-07-25 2017-06-20 Crestovo Llc Probiotic recolonisation therapy
US10369175B2 (en) 2000-07-25 2019-08-06 Crestovo Holdings Llc Probiotic recolonisation therapy
US9320763B2 (en) 2000-07-25 2016-04-26 Thomas Julius Borody Probiotic recolonisation therapy
US10772919B2 (en) 2000-07-25 2020-09-15 Crestovo Holdings Llc Probiotic recolonisation therapy
US9962414B2 (en) 2000-07-25 2018-05-08 Crestovo Holdings Llc Probiotic recolonisation therapy
US9901604B2 (en) 2000-07-25 2018-02-27 Crestovo Holdings Llc Probiotic recolonisation therapy
US9572842B2 (en) 2000-07-25 2017-02-21 Crestovo Llc Probiotic recolonisation therapy
US9572841B2 (en) 2000-07-25 2017-02-21 Crestovo Llc Probiotic recolonisation therapy
US9408872B2 (en) 2000-07-25 2016-08-09 Crestovo Llc Probiotic recolonisation therapy
CN100480370C (zh) * 2002-07-23 2009-04-22 雀巢技术公司 用于消化道神经肌肉功能的益生菌
CN103623010A (zh) * 2007-05-18 2014-03-12 雀巢产品技术援助有限公司 在外科手术前和/或外科手术后环境中的益生菌
CN101909643A (zh) * 2007-11-30 2010-12-08 巴斯德研究所 干酪乳杆菌菌株用于制备抑制肥大细胞活化之组合物的用途
CN101983237B (zh) * 2007-12-24 2013-06-12 康斯乔最高科学研究公司 改善与谷蛋白摄入相关之病症个体健康状况的微生物
CN104784694A (zh) * 2009-06-19 2015-07-22 杜邦营养生物科学有限公司 治疗糖尿病及相关病症的双歧杆菌
US10617724B2 (en) 2010-08-04 2020-04-14 Crestovo Holdings Llc Compositions for fecal floral transplantation and methods for making and using them and devices for delivering them
US10849937B2 (en) 2010-08-04 2020-12-01 Crestovo Holdings Llc Compositions for fecal floral transplantation and methods for making and using them and devices for delivering them
US11890307B2 (en) 2010-08-04 2024-02-06 Finch Therapeutics Holdings Llc Compositions for fecal floral transplantation and methods for making and using them and devices for delivering them
US9962413B2 (en) 2010-08-04 2018-05-08 Crestovo Holdings Llc Compositions for fecal floral transplantation and methods for making and using them and devices for delivering them
US11890308B2 (en) 2010-08-04 2024-02-06 Finch Therapeutics Holdings Llc Compositions for fecal floral transplantation and methods for making and using them and devices for delivering them
US11850269B2 (en) 2010-08-04 2023-12-26 Finch Therapeutics Holdings Llc Compositions for fecal floral transplantation and methods for making and using them and devices for delivering them
US10022406B2 (en) 2010-08-04 2018-07-17 Crestovo Holdings Llc Compositions for fecal floral transplantation and methods for making and using them and devices for delivering them
US11541080B2 (en) 2010-08-04 2023-01-03 Finch Therapeutics Holdings Llc Compositions for fecal floral transplantation and methods for making and using them and devices for delivering them
US10064899B1 (en) 2010-08-04 2018-09-04 Crestovo Holdings Llc Compositions for fecal floral transplantation and methods for making and using them and devices for delivering them
US11504403B2 (en) 2010-08-04 2022-11-22 Finch Therapeutics Holdings Llc Compositions for fecal floral transplantation and methods for making and using them and devices for delivering them
US11491193B2 (en) 2010-08-04 2022-11-08 Finch Therapeutics Holdings Llc Compositions for fecal floral transplantation and methods for making and using them and devices for delivering them
US11207356B2 (en) 2010-08-04 2021-12-28 Finch Therapeutics Holdings Llc Compositions for fecal floral transplantation and methods for making and using them and devices for delivering them
US10278997B2 (en) 2010-08-04 2019-05-07 Crestovo Holdings Llc Compositions for fecal floral transplantation and methods for making and using them and devices for delivering them
US11173183B2 (en) 2010-08-04 2021-11-16 Finch Therapeutics Holdings Llc Compositions for fecal floral transplantation and methods for making and using them and devices for delivering them
US11129859B2 (en) 2010-08-04 2021-09-28 Finch Therapeutics Holdings Llc Compositions for fecal floral transplantation and methods for making and using them and devices for delivering them
US10328107B2 (en) 2010-08-04 2019-06-25 Crestovo Holdings Llc Compositions for fecal floral transplantation and methods for making and using them and devices for delivering them
US11103541B2 (en) 2010-08-04 2021-08-31 Finch Therapeutics Holdings Llc Compositions for fecal floral transplantation and methods for making and using them and devices for delivering them
US11065284B2 (en) 2010-08-04 2021-07-20 Finch Therapeutics Holdings Llc Compositions for fecal floral transplantation and methods for making and using them and devices for delivering them
US10463702B2 (en) 2010-08-04 2019-11-05 Crestovo Holdings Llc Compositions for fecal floral transplantation and methods for making and using them and devices for delivering them
US10987385B2 (en) 2010-08-04 2021-04-27 Finch Therapeutics Holdings Llc Compositions for fecal floral transplantation and methods for making and using them and devices for delivering them
US10610551B2 (en) 2010-08-04 2020-04-07 Crestovo Holdings, Inc. Compositions for fecal floral transplantation and methods for making and using them and devices for delivering them
US10857188B2 (en) 2010-08-04 2020-12-08 Crestovo Holdings Llc Compositions for fecal floral transplantation and methods for making and using them and devices for delivering them
US10675309B2 (en) 2010-08-04 2020-06-09 Crestovo Holdings Llc Compositions for fecal floral transplantation and methods for making and using them and devices for delivering them
CN103561752B (zh) * 2011-03-09 2016-04-20 明尼苏达大学评议会 用于移植结肠微生物群的组合物和方法
US10286012B2 (en) 2011-03-09 2019-05-14 Regents Of The University Of Minnesota Compositions and methods for transplantation of colon microbiota
US10028980B2 (en) 2011-03-09 2018-07-24 Regents Of The University Of Minnesota Compositions and methods for transplantation of colon microbiota
CN103561752A (zh) * 2011-03-09 2014-02-05 明尼苏达大学评议会 用于移植结肠微生物群的组合物和方法
US9968638B2 (en) 2011-03-09 2018-05-15 Regents Of The University Of Minnesota Compositions and methods for transplantation of colon microbiota
US10251914B2 (en) 2011-03-09 2019-04-09 Regents Of The University Of Minnesota Compositions and methods for transplantation of colon microbiota
US12295974B2 (en) 2011-03-09 2025-05-13 Regents Of The University Of Minnesota Compositions and methods for transplantation of colon microbiota
US9649343B2 (en) 2011-03-09 2017-05-16 National Institutes of Health (NIH); U.S. Department of Health and Human Services (DHHS); The United States of America, NIH Division of Extramural Inventions and Tehnology Resources (DEITR) Compositions and methods for transplantation of colon microbiota
US11801269B2 (en) 2011-03-09 2023-10-31 Regents Of The University Of Minnesota Compositions and methods for transplantation of colon microbiota
US10286011B2 (en) 2011-03-09 2019-05-14 Regents Of The University Of Minnesota Compositions and methods for transplantation of colon microbiota
CN102899261B (zh) * 2011-03-11 2016-12-07 光晟生物科技股份有限公司 长双歧杆菌长亚种br022菌株的用途
CN102899261A (zh) * 2011-03-11 2013-01-30 光晟生物科技股份有限公司 可产生高免疫激活反应的长双歧杆菌长亚种分离株及可刺激免疫激活的组合物
US11542560B2 (en) 2012-05-25 2023-01-03 Board of Regents on Behalf of Arizona State University Microbiome markers and therapies for autism spectrum disorders
CN113862175A (zh) * 2014-12-23 2021-12-31 4D制药研究有限公司 免疫调控
US12161678B2 (en) 2015-05-14 2024-12-10 Finch Therapeutics Holdings Llc Compositions for fecal floral transplantation and methods for making and using them and device for delivering them
US10821138B2 (en) 2015-05-14 2020-11-03 Crestovo Holdings Llc Compositions for fecal floral transplantation and methods for making and using them and device for delivering them
US9901603B2 (en) 2015-05-14 2018-02-27 Crestovo Holdings Llc Compositions for fecal floral transplantation and methods for making and using them and device for delivering them
US11123377B2 (en) 2015-05-14 2021-09-21 Finch Therapeutics Holdings Llc Compositions for fecal floral transplantation and methods for making and using them and device for delivering them
US11202808B2 (en) 2015-05-22 2021-12-21 Arizona Board Of Regents On Behalf Of Arizona State University Methods for treating autism spectrum disorder and associated symptoms
US11357801B2 (en) 2016-06-15 2022-06-14 Arizona Board Of Regents On Behalf Of Arizona State University Methods for treating autism spectrum disorder and associated symptoms
US12186349B2 (en) 2016-07-01 2025-01-07 Regents Of The University Of Minnesota Compositions and methods for C. difficile treatment
US11819523B2 (en) 2016-07-01 2023-11-21 Regents Of The University Of Minnesota Compositions and methods for C. difficile treatment
US10195235B2 (en) 2016-08-03 2019-02-05 Crestovo Holdings Llc Methods for treating ulcerative colitis
US12390496B2 (en) 2016-08-03 2025-08-19 Finch Therapeutics Holdings Llc Methods for treating ulcerative colitis
US10561690B2 (en) 2016-08-03 2020-02-18 Crestovo Holdings Llc Methods for treating ulcerative colitis
US11071759B2 (en) 2016-08-03 2021-07-27 Finch Therapeutics Holdings Llc Methods for treating ulcerative colitis
US10092601B2 (en) 2016-10-11 2018-10-09 Crestovo Holdings Llc Compositions and methods for treating multiple sclerosis and related disorders
US11213549B2 (en) 2016-10-11 2022-01-04 Finch Therapeutics Holdings Llc Compositions and method for treating primary sclerosing cholangitis and related disorders
US11026978B2 (en) 2016-10-11 2021-06-08 Finch Therapeutics Holdings Llc Compositions and methods for treating multiple sclerosis and related disorders
US11529375B2 (en) 2017-04-05 2022-12-20 Finch Therapeutics Holdings Llc Compositions and methods for treating diverticulitis and related disorders
US11040073B2 (en) 2017-04-05 2021-06-22 Finch Therapeutics Holdings Llc Compositions and methods for treating diverticulitis and related disorders
US11433102B2 (en) 2017-04-05 2022-09-06 Finch Therapeutics Holdings Llc Compositions and methods for treating Parkinson's disease (PD) and related disorders
US11890306B2 (en) 2017-05-26 2024-02-06 Finch Therapeutics Holdings Llc Lyophilized compositions comprising fecal microbe-based therapeutic agents and methods for making and using same
US11865145B2 (en) 2017-08-07 2024-01-09 Finch Therapeutics Holdings Llc Compositions and methods for maintaining and restoring a healthy gut barrier
US11166990B2 (en) 2018-07-13 2021-11-09 Finch Therapeutics Holdings Llc Methods and compositions for treating ulcerative colitis
US12285447B2 (en) 2018-07-13 2025-04-29 Finch Therapeutics Holdings Llc Methods and compositions for treating ulcerative colitis
US11911419B2 (en) 2018-09-27 2024-02-27 Finch Therapeutics Holdings Llc Compositions and methods for treating epilepsy and related disorders
CN109929773A (zh) * 2019-01-10 2019-06-25 江苏德禧生物科技有限公司 一株可用于富硒培养的双歧杆菌及其活性蛋白和应用
US12290538B2 (en) 2019-07-19 2025-05-06 Finch Therapeutics Holdings Llc Methods and products for treatment of gastrointestinal disorders
CN116083327A (zh) * 2023-04-07 2023-05-09 天赋能(天津)功能食品研究发展有限公司 长双歧杆菌婴儿亚种及在缓解便秘、抗结肠组织炎症和改善肠道菌群方面的应用
CN116574659A (zh) * 2023-06-14 2023-08-11 江南大学 一株可缓解类风湿性关节炎的长双歧杆菌婴儿亚种及其应用

Also Published As

Publication number Publication date
IN2004KN00093A (enExample) 2006-03-03
IL160048A0 (en) 2004-06-20
WO2003010297A1 (en) 2003-02-06
EP1409644A1 (en) 2004-04-21
PE20030284A1 (es) 2003-05-01
MXPA04000738A (es) 2004-07-08
US20060121015A1 (en) 2006-06-08
BR0211442A (pt) 2004-11-09
CA2454803A1 (en) 2003-02-06
US20030092163A1 (en) 2003-05-15
JP2005508617A (ja) 2005-04-07
AU2002329006A1 (en) 2003-02-17

Similar Documents

Publication Publication Date Title
CN1639317A (zh) 益生菌唾液乳杆菌菌株
CN1556853A (zh) 益生菌干酪乳杆菌菌株
US11225641B2 (en) Probiotic Bifidobacterium strain
CN101688171B (zh) 益生双歧杆菌菌株
US20060121015A1 (en) Probiotic bifidobacterium strains
CN101679938B (zh) 益生双歧杆菌菌株
CN1342196A (zh) 用于治疗炎性疾病的双歧杆菌
AU2002329007A1 (en) "Probiotic Lactobacillus salivarius strains"
Li et al. In vitro and in vivo investigations of probiotic properties of lactic acid bacteria isolated from Chinese traditional sourdough
RU2302458C2 (ru) Пробиотический штамм lactobacillus salivarius (варианты), пробиотический препарат на их основе и способ лечения или предупреждения с использованием штаммов lactobacillus salivarius
HK1242734A1 (en) Probiotic bifidobacterium strain
AU2002328131A1 (en) Probiotic lactobacillus casei strains
IE20020624A1 (en) Probiotic Lactobacillus casei strains
ZA200400555B (en) Probiotic bifidobacterium strains.
ZA200400556B (en) Probiotic lactobacillus salivarius strains.
ZA200400557B (en) Probiotic lactobacillus casei strains.
IE20020620A1 (en) Probiotic Lactobacillus salivarius strains
IE20020626A1 (en) Probiotic Bifidobacterium strains

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication